Latest Opioid Stories
WILMINGTON, Del., March 31, 2015 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) reported that partner AstraZeneca announced today that MOVANTIK(TM) (naloxegol) has launched in the United States.
FLORHAM PARK, N.J., March 30, 2015 /PRNewswire/ -- Naldemedine, an investigational peripherally acting mu-opioid receptor antagonist (PAMORA) under development by Shionogi & Co., Ltd., met
--Company to host conference call today at 8:00 AM EDT-- WAYNE, Pa., March 25, 2015 /PRNewswire/ -- Egalet Corporation (Nasdaq: EGLT) ("Egalet"), a fully integrated specialty pharmaceutical
Enteric-Coated Buprenorphine Product Candidates (BuTab, REL-1028) to be Compared with Marketed Intravenous and Sublingual Formulations NEW YORK, March 24, 2015 /PRNewswire/ -- Relmada
AcelRx Announces Restructuring to Focus on Regulatory Approval of Zalviso and Clinical Development of ARX-04 REDWOOD CITY, Calif., March 20, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals, Inc.
SAN FRANCISCO, March 19, 2015 /PRNewswire/ -- Nektar Therapeutics (NASDAQ: NKTR) reported that partner AstraZeneca today announced a co-commercialisation agreement with Daiichi Sankyo, Inc.
PARSIPPANY, N.J., March 19, 2015 /PRNewswire/ -- Daiichi Sankyo, Inc.
SAP301 Trial to Study Sufentanil Sublingual Single-Dose Tablet for the Treatment of Moderate-to-Severe Acute Pain REDWOOD CITY, Calif., March 16, 2015 /PRNewswire/ -- AcelRx Pharmaceuticals,
WAYNE, Pa., March 16, 2015 /PRNewswire/ -- Egalet Corporation (Nasdaq: EGLT) ("Egalet") today reported financial results for the year ended December 31, 2014.
In most states, sharing narcotic opioid painkillers is equivalent to selling heroin ITASCA, Ill., March 12, 2015 /PRNewswire-USNewswire/ -- Today the